181 related articles for article (PubMed ID: 22214764)
1. Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.
Zhang CZ; Chen GG; Merchant JL; Lai PB
Cell Cycle; 2012 Jan; 11(2):322-34. PubMed ID: 22214764
[TBL] [Abstract][Full Text] [Related]
2. ATM phosphorylates ZBP-89 at Ser202 to potentiate p21waf1 induction by butyrate.
Bai L; Merchant JL
Biochem Biophys Res Commun; 2007 Aug; 359(3):817-21. PubMed ID: 17560543
[TBL] [Abstract][Full Text] [Related]
3. Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection.
Bai L; Kao JY; Law DJ; Merchant JL
Gastroenterology; 2006 Sep; 131(3):841-52. PubMed ID: 16952553
[TBL] [Abstract][Full Text] [Related]
4. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells.
Bajbouj K; Mawrin C; Hartig R; Schulze-Luehrmann J; Wilisch-Neumann A; Roessner A; Schneider-Stock R
J Neurooncol; 2012 May; 107(3):503-16. PubMed ID: 22270849
[TBL] [Abstract][Full Text] [Related]
5. ZBP-89 mediates butyrate regulation of gene expression.
Merchant JL; Bai L; Okada M
J Nutr; 2003 Jul; 133(7 Suppl):2456S-2460S. PubMed ID: 12840224
[TBL] [Abstract][Full Text] [Related]
6. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells.
Bai L; Merchant JL
J Biol Chem; 2000 Sep; 275(39):30725-33. PubMed ID: 10899165
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
[TBL] [Abstract][Full Text] [Related]
8. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.
Chen GG; Merchant JL; Lai PB; Ho RL; Hu X; Okada M; Huang SF; Chui AK; Law DJ; Li YG; Lau WY; Li AK
Am J Pathol; 2003 Jun; 162(6):1823-9. PubMed ID: 12759240
[TBL] [Abstract][Full Text] [Related]
9. ZBP-89 promotes growth arrest through stabilization of p53.
Bai L; Merchant JL
Mol Cell Biol; 2001 Jul; 21(14):4670-83. PubMed ID: 11416144
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
[TBL] [Abstract][Full Text] [Related]
11. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Oh ET; Park MT; Choi BH; Ro S; Choi EK; Jeong SY; Park HJ
Invest New Drugs; 2012 Apr; 30(2):435-42. PubMed ID: 20978925
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells.
Liu PY; Chan JY; Lin HC; Wang SL; Liu ST; Ho CL; Chang LC; Huang SM
Mol Cancer Res; 2008 Jul; 6(7):1204-14. PubMed ID: 18644983
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of ZBP-89 and its prognostic significance in hepatocellular carcinoma.
Zhang CZ; Cao Y; Yun JP; Chen GG; Lai PB
Histopathology; 2012 Jun; 60(7):1114-24. PubMed ID: 22372401
[TBL] [Abstract][Full Text] [Related]
14. p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB
Cell Cycle; 2015; 14(22):3602-12. PubMed ID: 26506264
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
[TBL] [Abstract][Full Text] [Related]
16. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
[TBL] [Abstract][Full Text] [Related]
17. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
Li D; Marchenko ND; Moll UM
Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
Li F; Wang T; Wang Z; Chen X; Liu R
Mol Med Rep; 2017 Nov; 16(5):6094-6101. PubMed ID: 28849080
[TBL] [Abstract][Full Text] [Related]
19. Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate.
Joseph J; Wajapeyee N; Somasundaram K
Int J Cancer; 2005 May; 115(1):11-8. PubMed ID: 15688418
[TBL] [Abstract][Full Text] [Related]
20. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
